5 Stocks US Congressmen Are Selling

4. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 83

Pfizer Inc. (NYSE:PFE) is an American biopharmaceutical company that develops injectable and anti-infective medicines, biosimilars, and vaccines for multiple medical ailments. 

John Rutherford is a Republican politician who was elected  from Florida’s 4th congressional district to be a member of the United States House of Representatives. Rutherford’s trade disclosures on February 17 revealed that he sold shares of Pfizer Inc. (NYSE:PFE) ranging between $1,001 and $15,000. 

Pfizer Inc. (NYSE:PFE) reported its fourth quarter results on February 9, posting a GAAP EPS of $0.59, missing estimates by $0.15. Although the Q4 revenue jumped 104% year-over-year to $23.84 billion, it missed market consensus by $362.61 million. 

On February 10, Mizuho analyst Vamil Divan lowered the price target on Pfizer Inc. (NYSE:PFE) to $55 from $56 and maintained a Neutral rating on the shares. While the initial fiscal 2022 guidance may have disappointed some investors, there is “room for significant upside” to Pfizer Inc. (NYSE:PFE)’s pipeline, including Comirnaty and Paxlovid, the analyst told investors in a research note. The analyst is looking for Pfizer Inc. (NYSE:PFE) to report further progress with its long-term outlook before he revises his rating for the stock.

Hedge fund sentiment around Pfizer Inc. (NYSE:PFE) is extremely bullish. In Q4 2021, 83 funds reported owning stakes in Pfizer Inc. (NYSE:PFE), compared to 74 funds in the earlier quarter. Coatue Management is a leading shareholder of the company, with a position worth roughly $609 million. 

Here is what Saturna Capital Amana Funds has to say about Pfizer Inc. (NYSE:PFE) in its Q3 2021 investor letter:

“The Fund’s strongest performer during the quarter was pharmaceutical manufacturer Pfizer. The company submitted trial data to the FDA for use of its COVID-19 vaccine for younger children, and it is widely expected that the FDA will approve it. Health authorities also began recommending booster shots of the Pfizer vaccine for select populations, further increasing demand for vaccinations.”